3phala Ayurcentre Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: 3phala Ayurcentre Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $17.1K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

3phala Ayurcentre Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $17.1K Trade | TransData Nexus

3phala Ayurcentre Private Limited

Indian Pharmaceutical Exporter · Ayurvedic & Herbal Products Specialist · $17.1K Total Trade · DGFT Verified

3phala Ayurcentre Private Limited is an Indian pharmaceutical exporter with a total trade value of $17.1K across 2 products in 1 therapeutic categories. Based on 72 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Arishta ($14.2K), Asava ($2.9K), .

3phala Ayurcentre Private Limited — Export Portfolio & Destination Treemap

3phala Ayurcentre Private Limited pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is 3phala Ayurcentre Private Limited? — Company Overview & Market Position

3phala Ayurcentre Private Limited is a privately held Indian company specializing in the export of Ayurvedic and herbal pharmaceutical formulations. Established on November 16, 2018, the company is registered under the Corporate Identification Number (CIN) U74999TN2018PTC125961. Headquartered in Chennai, Tamil Nadu, at New No. 19, Old No. 61, 27th Street, L Block, Anna Nagar East, the company operates within the business services sector. The authorized share capital is ₹1,000,000, with a paid-up capital of ₹100,000. As of the latest available data, the company remains active and compliant with regulatory requirements.

What Does 3phala Ayurcentre Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Arishta$14.2K 2Asava$2.9K

3phala Ayurcentre Private Limited Therapeutic Categories — 1 Specializations

Product Portfolio — Top 2 by Export Value

3phala Ayurcentre Private Limited exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Arishta	Ayurvedic & Herbal Products	$14.2K	51	1.0%	12
2	Asava	Ayurvedic & Herbal Products	$2.9K	21	0.6%	13

3phala Ayurcentre Private Limited exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $17.1K. The top category is Ayurvedic & Herbal Products (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

3phala Ayurcentre Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Specific details regarding the manufacturing facilities of 3phala Ayurcentre Private Limited are not publicly disclosed. The company's export activities, as indicated by trade data, suggest that it may operate through contract manufacturing or third-party facilities. The absence of publicly available information on in-house manufacturing capabilities limits a comprehensive assessment of its production capacities and specializations.

3Key Leadership

The company's leadership comprises directors Bhuvaneswari Hariharan, Periyasami Karthikeyan, Periyasamy Pachaiyammal, and Periyasami Marimuthu Manmalai. However, specific roles such as CEO, CFO, and other key executive positions are not publicly detailed. The lack of publicly available information on the executive team hinders a thorough understanding of the company's strategic direction and management structure.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does 3phala Ayurcentre Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

3phala Ayurcentre Private Limited's export data indicates shipments to various international markets, including Singapore. For instance, in July 2025, the company exported 50 bottles of Pathyakshadhatryadi Kashayam (200ml each) to Singapore. However, there is no publicly available information regarding the company's regulatory filings, approvals, or market access status in the United States, European Union, United Kingdom, Australia, or Japan. The absence of such data suggests limited or no presence in these regulated markets.

2Emerging Markets

The company's export activities, particularly to Singapore, indicate a presence in Southeast Asia. However, there is no publicly available information regarding its penetration into African, Latin American, or other Southeast Asian markets. Additionally, the lack of data on WHO prequalification status suggests that the company may not have pursued this certification, potentially limiting access to certain international markets.

3Geographic Strategy

The company's export data primarily reflects shipments to Singapore, indicating a focused geographic strategy. The absence of exports to other regions suggests a concentration risk, potentially exposing the company to market fluctuations in its primary export destination. Without information on diversification efforts or strategic direction, it is challenging to assess the company's long-term geographic strategy.

3phala Ayurcentre Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

There is no publicly available information regarding 3phala Ayurcentre Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history. The lack of such data suggests that the company may not have pursued FDA approvals, potentially limiting its access to the U.S. pharmaceutical market.

2WHO & EU GMP

The company's export data does not indicate WHO prequalification or EU Good Manufacturing Practice (GMP) certifications. The absence of such certifications may restrict the company's ability to access certain international markets that require these standards.

3CDSCO & Indian Regulatory

Specific details regarding 3phala Ayurcentre Private Limited's manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), approvals from state drug controllers, or export No Objection Certificates (NOCs) are not publicly available. The lack of such information limits the ability to assess the company's compliance with Indian regulatory requirements.

3phala Ayurcentre Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

The Ayurvedic and herbal pharmaceutical export market is competitive, with numerous companies offering similar products. Without specific data on competitors' market shares or a head-to-head analysis, it is challenging to position 3phala Ayurcentre Private Limited within the competitive landscape.

2Key Differentiators

The company's focus on Ayurvedic and herbal pharmaceutical formulations positions it within a niche market segment. However, without detailed information on product offerings, quality standards, or unique selling propositions, it is difficult to identify specific competitive advantages or differentiators.

3Strategic Position

The company's export data suggests a focus on Ayurvedic and herbal pharmaceutical formulations. However, without information on its strategic direction, such as emphasis on generics, specialty products, biosimilars, or Contract Development and Manufacturing Organization (CDMO) services, it is challenging to assess its current strategic position or future outlook.

Buyer Due Diligence Brief — Evaluating 3phala Ayurcentre Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

The company's export data indicates shipments to Singapore, suggesting a track record in international trade. However, the limited volume of exports and the absence of information on export consistency or reliability indicators make it difficult to assess the company's overall performance as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering 3phala Ayurcentre Private Limited as a supplier:

FDA Approval: To verify FDA approval, consult the FDA's official database or contact the company directly.

WHO-GMP Certification: Check the WHO's official website or contact the company for certification details.

EU GMP Certification: Verify through the European Medicines Agency (EMA) or the company's official communications.

Frequently Asked Questions — 3phala Ayurcentre Private Limited

How many pharmaceutical products does 3phala Ayurcentre Private Limited export from India?

3phala Ayurcentre Private Limited exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Arishta ($14.2K), Asava ($2.9K). Total export value is $17.1K.

What is 3phala Ayurcentre Private Limited's total pharmaceutical export value?

3phala Ayurcentre Private Limited's total pharmaceutical export value is $17.1K, based on 72 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does 3phala Ayurcentre Private Limited cover?

3phala Ayurcentre Private Limited exports across 1 therapeutic categories. The largest are Ayurvedic & Herbal Products (100.0%, 2 products).

Get Full 3phala Ayurcentre Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.